Stockscreener 앱 받기
2.57
16.83%
-0.52
시장 영업 전:
2.66
0.09
+3.50%
Esperion Therapeutics Inc 주식(ESPR)의 최신 뉴스
Is Esperion Therapeutics Inc. stock a buy on dips2025 Trading Volume Trends & Safe Entry Trade Reports - newser.com
Published on: 2025-10-09 02:49:28 - newser.com
Esperion Therapeutics Inc. (ESPR) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Esperion Announces Public Offering to Raise $70.2 Million - TipRanks
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap DownShould You Sell? - MarketBeat
Esperion Therapeutics’ Bold Move: Stock Offering at $2.50 - StocksToTrade
Esperion Therapeutics prices $75M public offering - MSN
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why Is Esperion Therapeutics Stock Sinking Premarket Today? - Stocktwits
Esperion Therapeutics Prices $75 Million Share Offering - MarketScreener
Esperion prices $75 million public offering of common stock By Investing.com - Investing.com Nigeria
Esperion Announces Pricing of Public Offering of Common Stock - The Manila Times
Esperion prices public offering of 30 million shares at $2.50 each - MarketScreener
Esperion Therapeutics Announces Pricing of $75 Million Public Offering of Common Stock - Quiver Quantitative
$75M Raise — Esperion Prices 30M Shares to Fund Oral LDL‑C Program - Stock Titan
Esperion Announces Pricing of Public Offering of Common Stock - GlobeNewswire Inc.
Esperion Therapeutics Experiences Evaluation Revision Amidst Mixed Market Indicators and Performance Trends - Markets Mojo
Esperion announces proposed public offering of common stock - MarketScreener
ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up - MSN
Esperion launches public offering of common stock to raise capital By Investing.com - Investing.com Australia
Esperion Therapeutics tumbles after stock offering launch - TradingView
Esperion Announces Strategic Expansion Plans for Bempedoic Acid - TipRanks
Esperion launches proposed public offering of common stock; shares fall 21% (ESPR:NASDAQ) - Seeking Alpha
Esperion stock tumbles after announcing public offering - Investing.com
Esperion Announces Proposed Public Offering of Common Stock - Stock Titan
Will Esperion Therapeutics Inc. outperform the marketMarket Activity Recap & Stepwise Entry and Exit Trade Signals - newser.com
Will Esperion Therapeutics Inc. rebound enough to break evenRate Hike & Low Risk Entry Point Tips - newser.com
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL and NEXLIZET Prior to April 19, 2040 - MarketScreener
Esperion’s Share Surge Following Patent Lawsuit Settlement - StocksToTrade
Esperion Therapeutics Gains Traction with Settlement and Strategic Moves - timothysykes.com
Esperion’s Legal Victory Against Dr. Reddy’s Sparks Stock Surge - StocksToTrade
Esperion Shares Surge Amid Patent Lawsuit Settlement - timothysykes.com
Analyzing drawdowns of Esperion Therapeutics Inc. with statistical toolsPortfolio Update Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Has Esperion Therapeutics Inc. found a price floorWeekly Market Summary & Weekly High Potential Stock Alerts - newser.com
Is Esperion Therapeutics Inc. stock attractive for hedge fundsOptions Play & Daily Profit Focused Stock Screening - newser.com
Will Esperion Therapeutics Inc. (0ET) stock see valuation expansion2025 Earnings Impact & Fast Gaining Stock Reports - newser.com
Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockAnalyst Downgrade & Free Long-Term Investment Growth Plans - newser.com
What does recent volatility data suggest for Esperion Therapeutics Inc.July 2025 Drop Watch & Reliable Price Breakout Alerts - newser.com
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) and Lead Plaintiff Deadline: March 14, 2016 - ACCESS Newswire
Esperion Therapeutics Surges on Patent Settlement With Dr. Reddy’s - StocksToTrade
Esperion Shares Soar Amid Resolving Patent Dispute - timothysykes.com
Is Esperion Therapeutics Inc a good long term investmentEquity Performance Review & In-Depth Analyst Ratings Explained Simply - earlytimes.in
Esperion settles patent litigation with Dr. Reddy’s Laboratories By Investing.com - Investing.com Nigeria
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpTime to Buy? - MarketBeat
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. - GlobeNewswire
Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs - Seeking Alpha
Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug - MarketScreener
Esperion settles patent litigation with Dr. Reddy’s Laboratories - Investing.com
Esperion Announces Settlement Agreement with Dr. Reddy’s Laboratories Regarding NEXLETOL and NEXLIZET Patent Litigation - Quiver Quantitative
Esperion reaches settlement agreement with ANDA filer - MarketScreener
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040 | Dow Theory Letters - FinancialContent
0.54%
0.35%
자본화:
|
볼륨(24시간):